Identification of TM Cell Markers
About the Research Project
Program
Award Type
Standard
Award Amount
$90,000
Active Dates
March 31, 2007 - September 30, 2009
Grant ID
G2007055
Goals
In this application we propose studies to identify differential markers of the three distinct cell types of the aqueous outflow pathway using the most modern, state of the art techniques. It is our hope that characterization of gene expression patterns of distinct cell types of the outflow pathway will lay the foundation for research by novel, more accurate approaches for understanding the pathogenic mechanisms of glaucoma.
Summary
Glaucoma is the second leading cause of blindness in the world. Nearly 2.5 million individuals in the US and 70 million worldwide are affected by this blinding disease. Elevated IOP due to reduction in aqueous outflow facility is a major causal risk factor. In humans, the aqueous outflow pathway is constituted of Schlemm’s canal (SC) lined by its endothelial cells, and trabecular meshwork (TM) which is divided into the corneoscleral (CS) portion with its endothelial-like TM cells and the juxtacanalicular (JCT) portion with its fibroblast-like TM cells. The functional differences and relative importance of the different cell populations residing in the outflow pathway is a subject of great debate in the field. While the three cell types of the outflow pathway can be readily distinguished in tissue sections based on distinct morphology, no specific markers have been identified that distinguish JCT and CS cells from one another. Clearly, for the analyses and interrogation of each cell type of the aqueous outflow pathway with respect to its role in the outflow resistance and the pathogenesis of glaucoma, availability of robust markers that would permit preparation of pure cultures of each cell type is a prerequisite. In this application we propose studies to identify differential markers of the three distinct cell types of the aqueous outflow pathway using the most modern, state of the art techniques.
Related Grants
National Glaucoma Research
Maldevelopment of Schlemm's Canal in Children with Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Revathi Balasubramanian, PhD
Current Organization
Columbia University
Maldevelopment of Schlemm's Canal in Children with Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Revathi Balasubramanian, PhD
Current Organization
Columbia University
National Glaucoma Research
Using Artificial Intelligence to Discover Genetic Risk Factors for Glaucoma Worsening
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Nazlee Zebardast, MD, MPH
Current Organization
Massachusetts Eye and Ear Infirmary
Using Artificial Intelligence to Discover Genetic Risk Factors for Glaucoma Worsening
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Nazlee Zebardast, MD, MPH
Current Organization
Massachusetts Eye and Ear Infirmary
National Glaucoma Research
Understanding Optic Nerve Head Astrocyte Contributions to Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Evan Cameron, PhD
Current Organization
Cleveland Clinic - Lerner Research Institute
Understanding Optic Nerve Head Astrocyte Contributions to Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Evan Cameron, PhD
Current Organization
Cleveland Clinic - Lerner Research Institute